CLDI — Calidi Biotherapeutics Inc.

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Calidi Biotherapeutics Inc.

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-40… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$0.18
Market Cap$3.7M
Float10.7M
Shares Outstanding19.3M
Price/Sales (TTM)50.83
vs. Analyst Target+66569.3% to analyst PT
Dividend RateNone
Analyst Target Price$120.00 (1 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 N/A -$7.9M N/A -$6.7M
2021 $449,000 -$10.9M $355,000 -$9.4M
2022 $45,000 -$25.4M -$229,000 -$25.0M
2023 N/A -$29.2M -$1.3M -$24.2M
2024 N/A -$22.1M -$1.5M -$19.7M
2025 N/A -$19.9M -$1.7M -$18.6M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$5.7M
Sep 2025 N/A -$5.1M
Dec 2025 N/A -$4.1M
Mar 2026 N/A -$4.1M

Ownership & Float

Insider Ownership2.4%
Institutional Ownership4.5%
Short Float28.4%
% of All Funds Holding0.32%
Number of Funds Holding26

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$0.24Near-term / short-term trend
Weekly40-Week SMA$1.01Medium-term trend
Weekly80-Week SMA$5.65Cyclical trend (business cycle)
Weekly200-Week SMA$392.86Secular trend (multi-year)
Monthly10-Month SMA$0.99Near-term monthly trend
Monthly20-Month SMA$5.48Medium-term monthly trend
Monthly40-Month SMA$253.11Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$13.80 resistance 1.78x 15 months ago
$25.40 resistance 1.66x 16 months ago
$69.00 resistance 6.39x 24 months ago

Historical Earnings Reactions (17 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.43% 0.00% 35.29% 18.48% -12.67%
1 Day 6.42% 0.00% 41.18% 60.19% -6.18%
1 Week 3.42% 0.00% 47.06% 107.00% -24.73%
2 Weeks 4.59% 0.20% 58.82% 128.31% -68.86%
1 Month -11.07% 0.10% 52.94% 12.63% -67.47%

Next earnings: August 2, 2026 (68 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday -0.80% 34.4% 212
Tuesday 0.11% 34.3% 236
Wednesday -0.24% 36.3% 234
Thursday -0.09% 35.7% 227
Friday -1.01% 33.0% 230

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 4.5%

Insider Transactions — Smart Summary

Total insider ownership: 2.4%

12-Month Insider Activity Summary

Total Filings5
Net Value+$55,000
Net Shares Change226,650
% of Float2.1%
C-Suite Filings2
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Leftwich Scott +$250,000 1 1 buy
Schoeneck James A +$150,000 1 1 buy
Poma Eric E Chief Executive Officer +$50,000 1 1 buy
Jackson Andrew C. Chief Financial Officer +$5,000 1 1 buy
Camaisa Allan -$1,236.75 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-08-25 – 2025-08-25 4 4 +$455,000 2 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-08-25 Poma Eric E Chief Executive Officer +$50,000 Transaction at $2.00, now -91.0%
2025-08-25 Jackson Andrew C. Chief Financial Officer +$5,000 Transaction at $2.00, now -91.0%
2025-08-25 Schoeneck James A +$150,000 Transaction at $2.00, now -91.0%
2025-08-25 Leftwich Scott +$250,000 Transaction at $2.00, now -91.0%
2025-12-16 Camaisa Allan -$1,236.75 Transaction at $1.46, now -87.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Calidi Biotherapeutics Inc. (CLDI) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CLDI on Trend Edge →